Department of NutritionSchool of Public Health, Harvard University, Boston, Massachusetts 02120, USA.
AIDS. 2012 Mar 13;26(5):577-85. doi: 10.1097/QAD.0b013e32834f9851.
To explore the predictors of weight loss after highly active antiretroviral therapy (HAART) initiation in a large cohort of HIV-infected adults living in Dar es Salaam, Tanzania.
Cross-sectional and longitudinal analysis of a cohort of HIV-infected adults on HAART.
HIV-infected adults (n = 18 965) were enrolled between November 2004 to December 2009 in Dar es Salaam, Tanzania. Log-binomial regression and Cox proportional hazard regression were used to explore the predictors of short-term (3 months) and long-term significant weight loss (≥ 5%) after HAART initiation.
At 3 months after HAART initiation, 8% patients lost greater than or equal to 5% weight. Underweight patients at initiation gained more weight than other body mass index (BMI) groups. Younger or older than age group 30-39, lower socioeconomic status (SES), higher BMI, lower hemoglobin, difficulty breathing, loss of appetite, nausea/vomiting at baseline were associated with the risk of significant weight loss at 3 months after initiation. During a median follow-up period of 10 months [interquartile range (IQR) 4-20 months], 31% patients had experienced an initial significant weight loss after HAART initiation. In addition to time-varying CD4 cell count and hemoglobin level, age, sex, baseline BMI and having loss of appetite, and nausea/vomiting at baseline were associated with the risk of long-term significant weight loss.
Our study suggested that a significant percentage of patients continue to lose weight after HAART initiation. Our findings on the effect of socio-demographics, symptoms and diseases, biomedical indicators in relation to weight loss provide important information that has significant practical implications.
在坦桑尼亚达累斯萨拉姆的一个大型 HIV 感染成年人队列中,探索高效抗逆转录病毒治疗(HAART)启动后体重减轻的预测因素。
对接受 HAART 的 HIV 感染成年人队列进行横断面和纵向分析。
HIV 感染成年人(n = 18965)于 2004 年 11 月至 2009 年 12 月在坦桑尼亚达累斯萨拉姆入组。采用对数二项式回归和 Cox 比例风险回归来探索 HAART 启动后短期(3 个月)和长期(≥5%)显著体重减轻的预测因素。
在 HAART 启动后 3 个月,8%的患者体重减轻≥5%。起始时体重不足的患者比其他 BMI 组体重增加更多。年龄小于或大于 30-39 岁年龄组、较低的社会经济地位(SES)、较高的 BMI、较低的血红蛋白、呼吸困难、食欲减退、恶心/呕吐基线与启动后 3 个月显著体重减轻的风险相关。在中位随访期 10 个月(四分位间距 [IQR] 4-20 个月)内,31%的患者在接受 HAART 治疗后经历了初始显著体重减轻。除了时间变化的 CD4 细胞计数和血红蛋白水平外,年龄、性别、基线 BMI 以及基线时出现食欲减退和恶心/呕吐与长期显著体重减轻的风险相关。
我们的研究表明,相当一部分患者在接受 HAART 后继续体重减轻。我们关于社会人口统计学、症状和疾病、与体重减轻相关的生物医学指标对体重减轻的影响的发现提供了重要的信息,具有重要的实际意义。